文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气

成人心脏手术体外循环期间维持极低潮气量通气与正压呼气末压对比停止通气:一项随机临床试验

Maintaining ventilation with very low tidal volume and positive-end expiratory pressure versus no ventilation during cardiopulmonary bypass for cardiac surgery in adults: a randomized clinical trial.
PubMed 文献 · Intensive Care Med · 2025-05-05
一句话结论体外循环期间维持极低潮气量通气(2.5 mL/kg预测体重、PEEP 5-7 cmH2O)未减少术后28天感染,且抗生素使用更多。

在法国6家医院进行的多中心、单盲随机试验纳入1362例择期体外循环心脏手术成人患者,比较体外循环期间维持极低潮气量通气(MV+组,潮气量2.5 mL/kg预测体重、PEEP 5-7 cmH2O)与停止通气(MV-组)对术后28天内所有类型感染的影响。主要结局感染发生率MV-组10.9%(74/680) vs MV+组10.0%(68/682),相对风险0.92(95%CI 0.67-1.25;P=0.58),无统计学显著差异。MV+组抗生素使用高于MV-组(发生率比1.08;95%CI 1.02-1.15;P=0.02)。其他次要结局及不良事件发生率两组无显著差异。结论:体外循环期间维持极低潮气量通气未减少术后28天感染,且观察到抗生素使用意外增加。

要点

  • 体外循环期间维持通气(潮气量2.5 mL/kg预测体重、PEEP 5-7 cmH2O)未减少术后28天感染:MV-组10.9% vs MV+组10.0%,相对风险0.92(95%CI 0.67-1.25;P=0.58)。
  • MV+组抗生素使用高于MV-组:发生率比1.08(95%CI 1.02-1.15;P=0.02)。
  • 两组其他次要结局及不良事件发生率无显著差异。
  • 该试验为多中心、单盲、随机对照,纳入择期体外循环心脏手术成人患者。
  • 主要结局为术后28天内所有类型感染,共1362例患者随机分组。

适用人群与场景

  • 法国6家医院纳入的成人患者,接受择期体外循环心脏手术。

诊断标准与关键阈值

  • 主要结局:术后28天内所有类型感染的发生。
  • 次要结局包括抗生素暴露天数等6项。

处置流程与药物剂量

  • MV+组:体外循环期间维持机械通气,潮气量2.5 mL/kg预测体重,PEEP 5-7 cmH2O。
  • MV-组:体外循环期间气管导管与呼吸机断开。

研究设计与关键结果

  • 多中心、单盲、随机临床试验,纳入1362例择期体外循环心脏手术成人患者,在法国6家医院进行。
  • 主要结局:术后28天内感染发生率MV-组10.9%(74/680) vs MV+组10.0%(68/682),相对风险0.92(95%CI 0.67-1.25;P=0.58)。
  • 抗生素使用:MV+组高于MV-组,发生率比1.08(95%CI 1.02-1.15;P=0.02)。
  • 其他次要结局及不良事件发生率两组无显著差异。

证据类型、等级与局限

  • 证据类型:多中心、单盲、随机临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于择期体外循环心脏手术成人患者,体外循环期间维持极低潮气量通气(2.5 mL/kg预测体重、PEEP 5-7 cmH2O)未减少术后28天感染,且与抗生素使用增加相关(发生率比1.08;95%CI 1.02-1.15;P=0.02)。
  • 原文未据此给出推荐。

指南或共识出处

  • 试验注册:ClinicalTrials.gov(NCT03372174)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Cardiopulmonary bypass (CPB) during cardiac surgery mechanically circulates and oxygenates the blood, bypassing the heart and lungs. Despite limited evidence, maintaining mechanical ventilation (MV) during CPB is recommended, as ventilator strategies during surgery may reduce the occurrence of postoperative infections. We aimed to determine whether maintaining MV for cardiac surgery would decrease postoperative infections compared with stopping MV during CPB.

METHODS: We conducted a multicenter, single-blind, randomized trial among adult patients undergoing scheduled cardiac surgery with CPB in six hospitals in France. During CPB, the tracheal tube was disconnected from the ventilator in the control group (MV- group). In the MV + group, ventilation was maintained during CPB with very low tidal volume ventilation, using a tidal volume of 2.5 mL/kg of predicted body weight, with 5-7 cmH2O positive end expiratory pressure. The primary outcome was the occurrence of all types of postoperative infections within the first 28 days after surgery. There were six secondary evaluation criteria including the number of days of exposure to antibiotics.

RESULTS: A total of 1362 patients were enrolled in the study. Postoperative infection occurred in 74 out of 680 patients (10.9%) in the MV- group, compared to 68 out of 682 patients (10.0%) in the MV + group (relative risk, 0.92; 95% confidence interval [CI] 0.67-1.25; p = 0.58). Antibiotic use was higher in the MV + group than in the MV- group (incidence risk ratio, 1.08; 95% CI 1.02-1.15; p = 0.02). There were no significant differences between the groups for all other secondary outcomes or for the incidence of adverse events.

CONCLUSIONS: Maintaining very low tidal volume ventilation with positive end-expiratory pressure during CPB did not reduce postoperative infections at 28 days compared to when mechanical ventilation was stopped during CPB. An unexpectedly higher use of antibiotics was observed when ventilation was maintained.

TRIAL REGISTRATION: ClinicalTrials.gov (NCT03372174).

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Tadié JM, Ouattara A, Laviolle B, et al. Maintaining ventilation with very low tidal volume and positive-end expiratory pressure versus no ventilation during cardiopulmonary bypass for cardiac surgery in adults: a randomized clinical trial. Intensive Care Med. 2025. PMID: 40323450. doi:10.1007/s00134-025-07901-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。